BN Business News
Add your company to Business Communicator →

Business · 07/04/2014Updated: 10/17/2026 · 1 min read

FDA Clears Path for SKELAXIN Tablets, 400mg, to be Approved via Abbreviated New Drug Applications

The US Food and Drug Administration has made a determination that SKELAXIN tablets, 400mg, were not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications for the medication.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →